Publications by authors named "Sorina-Dana Mihailescu"
Article Synopsis
- * Conducted in France from 2018 to 2022, the study found that 13.1% of the 183 patients experienced a NE, with adverse events (AEs) like rheumatism reactivation being the most common.
- * The results suggest that a careful, practitioner-supervised transition to biosimilars can lower the risk of NE, highlighting the importance of shared medical decision-making for effective patient outcomes.
Article Synopsis
- The study investigates the use of weekly adalimumab in children suffering from non-infectious chronic anterior uveitis (CAU), which is often difficult to treat.
- Out of 42 children with CAU, 64.3% were treated with adalimumab, and 40.7% of those required an increase to weekly doses, achieving inflammation control in 63.6% of cases after 3 and 6 months.
- The findings suggest that weekly adalimumab is effective and safe for managing CAU in children, paving the way for it to be considered before switching to other biologic treatments, although more controlled studies are recommended.
Context: Bone marrow biopsy (BMB) is a common procedure in haematology used for the diagnosis and evaluation of response treatment. Because the procedure is difficult for haematologists to perform, patients often experience pain and stress. On Control, a system device, was introduced in the 2000s and uses a drill-powered needle to perform BMB.
View Article and Find Full Text PDFArticle Synopsis
- The study looked at how the size of tumors in Hodgkin's lymphoma patients could help predict their chances of staying healthy for 5 years after treatment.
- They included 179 patients who received two different types of treatments (BEACOPP or ABVD).
- The results showed that measuring the total tumor size (TMTV) at the beginning helped doctors understand who might have a better or worse chance of not getting worse and responding well to treatment.
Sarcopenia is frequent in patients treated with radiation therapy (RT) or radiochemotherapy (RTCT) for head and neck squamous cell carcinomas. Sarcopenia is associated with poor disease-free survival and overall survival outcomes. Sarcopenia is not associated with a higher rate of treatment-related toxicity.
View Article and Find Full Text PDFWe conducted a retrospective study to analyze the prognostic factors impacting the overall survival (OS) and progression-free survival (PFS) of diffuse large B-cell lymphoma (DLBCL) patients undergoing first-line therapy and admitted to intensive care unit (ICU) compared to a control cohort who did not required ICU admission. Between January 1, 2008, and December 31, 2018, 828 patients were diagnosed with DLBCL at our institution, including 72 patients who were required ICU admission during disease course. Among them, forty-five patients undergoing homogeneous first-line therapy with /R-CHOP-like regimen and ICU-admitted were selected for the present analysis.
View Article and Find Full Text PDFThe metabolic tumour volume (MTV) is an independent prognostic indicator in diffuse large B-cell lymphoma (DLBCL). However, its measurement is not standardised and is subject to wide variations depending on the method used. This study aimed to compare the reproducibility of MTV measurement as well as the thresholds obtained for each method and their prognostic values.
View Article and Find Full Text PDFBackground: Ambulatory surgery lowers hospitalisation costs, shortens the time to return to work but requires caution regarding socioenvironmental risk factors for complications and rehospitalisation.
Methods: This was a single-centre prospective cross-sectional observational study conducted in a university hospital centrein January 2017. The primary objective was to assess the rate of conversion from ambulatory surgery to conventional hospitalisation or emergency department visit within 30 days following discharge from ambulatory unit.
Purpose: Chemoradiotherapy is the reference curative-intent treatment for nonresectable locally advanced non-small-cell lung carcinoma (NSCLC), with unsatisfactory survival, partially due to radiation resistance in hypoxic tissues. The objective was to update survival and toxicity at 3 years following radiotherapy boost to hypoxic tumours in NSCLC patients treated with curative-intent chemoradiotherapy.
Methods: This was an open-label, nonrandomized, multicentre, phase II clinical trial.